论文部分内容阅读
目的：评价玻璃体腔注射康柏西普治疗糖尿病黄斑水肿（DME）的疗效。方法：回顾分析21例（25眼）接受康柏西普0.5mg玻璃体腔注射治疗的DME患者，对比其治疗前及治疗后的最佳矫正视力及黄斑中心厚度的变化。结果：治疗后患者视力明显提高，CMT平均值治疗前为（529.35±158.15）um，治疗后4、8、12周均较前降低（t=3.51、3.25、3.53，p＜0.05），治疗后末次随诊为（368.50+±151.43）um，治疗前后差异有统计学意义（t=4.518，p=0.000）。结论：玻璃体腔注射康柏西普后，黄斑水肿明显消退，视力稳定并提高，未见明显不良反应，值得临床推广。“,”Objective This study was to evaluate the eefficacy of Conbercept on diabetic macular edema.Methods Retrospective analysis of 21 cases (25) to accept the conbercept 0.5mg intravitreal treatment of patients with DME, compare changes before the treatment and after treatment on the best corrected visual acuity (BCVA)and the central macular thickness(CMT).RsultsTheBCVA was improved significantly after treatment,The man central macular thickness was(529.35±158.15)μm in preinjection and (368.50±151.43)μm in postinjection,showing a statisticaly significant difference between them(t=4.518,P=0.000).ConclusionThe intravitreal injection of conbercept can relieve macular edema and damage of visual function,with no significant adverse reactions.